Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Tekla Life Sciences Investors(HQL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HQL
11/06/2026: HQL (3-star) is currently NOT-A-BUY. Pass it for now.
Tekla Life Sciences Investors (HQL) is a closed-end fund that offers investors targeted exposure to the dynamic biotechnology and pharmaceutical sectors. The fund is known for its ability to invest in both publicly traded equities and private placements, providing access to early-stage innovations often unavailable to typical retail investors. Its primary investment story revolves around capitalizing on medical breakthroughs and long-term sector growth. However, investors should be aware that the fund carries high volatility and regulatory risks inherent to the biotech industry. HQL may be a suitable fit for growth-oriented investors looking for specialized management, provided they understand the cyclical nature of the underlying assets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The focus on biotechnology and life sciences provides exposure to high-growth innovation. |
| Momentum investor | Mixed fit | Strong fit while signal remains positive, as the fund is highly sensitive to biotech sector momentum. |
| Value investor | Weak fit | The biotech sector often trades at high multiples, making it less suitable for traditional value investors. |
| Dividend investor | Mixed fit | While it pays distributions, these are often driven by capital gains rather than stable, high-yield underlying dividends. |
| Low-risk investor | Weak fit | The inherent volatility of the life sciences industry creates a high-risk profile. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are prone to sharp moves based on clinical trial outcomes. |
| Valuation risk | Medium / high | Growth expectations in biotech can lead to overvaluation relative to fundamentals. |
| Competition risk | Medium | Competition from larger, diversified healthcare funds limits pricing power for the fund's management. |
| Business quality | Medium | The quality of the portfolio depends heavily on the success of external biotech companies. |
| Dividend income | Medium | Distributions are subject to market volatility and are not guaranteed. |
| Execution risk | Medium | The fund manager's ability to pick successful winners is paramount to performance. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 78.47% | Avg. Invested days 68 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 538.22M USD | Price to earnings Ratio 2.72 | 1Y Target Price - |
Price to earnings Ratio 2.72 | 1Y Target Price - | ||
Volume (30-day avg) 120.8K shares | Beta 0.73 | 52 Weeks Range 14.15 - 22.04 | Updated Date 11/08/2026 |
52 Weeks Range 14.15 - 22.04 | Updated Date 11/08/2026 | ||
Dividends yield (FY) 11.00% | Basic EPS (TTM) 6.64 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Sciences Equity Investments | Publicly traded biotech and pharma stocks. | The fund grows money by picking stocks that gain value as their drug pipelines succeed. |
| Private Placements | Investment in unlisted biotech ventures. | The fund invests in private companies to capture early-stage growth before they go public. |
Valuation
Trailing PE 2.72 | Forward PE - | Enterprise Value 549.23M | Price to Sales(TTM) 2.91 |
Enterprise Value 549.23M | Price to Sales(TTM) 2.91 | ||
Enterprise Value to Revenue 2.77 | Enterprise Value to EBITDA - | Shares Outstanding 30.41M | Shares Floating - |
Shares Outstanding 30.41M | Shares Floating - | ||
Percent Insiders - | Percent Institutions 38.46 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.